Phase 2 Plasma Cell Leukemia Clinical Trials
12 recruitingPhase 2
What is a Phase 2 trial?
Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.
Showing 1–12 of 12 trials
Recruiting
Phase 1Phase 2
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
T-lymphoblastic LymphomaRelapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL+3 more
Beijing Biotech96 enrolled1 locationNCT07523555
Recruiting
Phase 2
IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia
Relapsed/Refractory Multiple MyelomaPlasma Cell Leukemia (PCL)
The First Hospital of Jilin University25 enrolled1 locationNCT07509086
Recruiting
Phase 2
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
Multiple MyelomaPlasma Cell Leukemia
University of Utah120 enrolled1 locationNCT05405387
Recruiting
Phase 2
A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05870917
Recruiting
Phase 2
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Multiple MyelomaPlasma Cell Leukemia
University of Utah40 enrolled1 locationNCT06517017
Recruiting
Phase 1Phase 2
Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Plasma Cell LeukemiaUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm DefinitionsCytogenetics Ultra High Risk+4 more
Institute of Hematology & Blood Diseases Hospital, China50 enrolled1 locationNCT07109323
Recruiting
Phase 2
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia
Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT05979363
Recruiting
Phase 2
ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia
Multiple Myeloma, Plasma Cell Leukemia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07106684
Recruiting
Phase 2
Allo HSCT Using RIC and PTCy for Hematological Diseases
Acute Myelogenous LeukemiaMyelodysplastic SyndromesLeukemia, Myeloid+15 more
Masonic Cancer Center, University of Minnesota56 enrolled1 locationNCT05805605
Recruiting
Phase 2
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Lymphocytic Leukemia+13 more
Masonic Cancer Center, University of Minnesota300 enrolled1 locationNCT03314974
Recruiting
Phase 2
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Multiple MyelomaPrimary Plasma Cell LeukemiaExtramedullary Multiple Myeloma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology54 enrolled1 locationNCT06140966
Recruiting
Phase 2
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L
Primary Plasma Cell Leukemia
Hellenic Society of Hematology43 enrolled7 locationsNCT06636552